U.S. FDA Approves Updated Label for ADSTILADRIN to Enable Faster Thawing and Improve Clinical Efficiency
Ferring Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved a label update for ADSTILADRIN® (nadofaragene firadenovec-vncg), introducing an accelerated water-bath thawing method that significantly reduces preparation time. This new approach allows the therapy to be thawed in approximately 25 minutes at 25°C (77°F), offering healthcare providers a more efficient and streamlined process for clinical use.
This update marks an important advancement in the handling and administration of ADSTILADRIN, helping to optimize workflows in healthcare settings while maintaining product stability and effectiveness. By reducing the time required to prepare the therapy, the updated label supports improved operational efficiency and enhances the overall experience for both providers and patients.
Advancing Treatment Efficiency in Bladder Cancer Care
ADSTILADRIN holds a unique position in oncology as the first and only FDA-approved non-replicating intravesical gene therapy designed to treat adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), specifically carcinoma in situ (CIS), with or without papillary tumors (Ta/T1).
Bladder cancer remains a significant health concern in the United States, ranking as the sixth most commonly diagnosed cancer. Among these cases, approximately 75% are classified as NMIBC. Patients with high-risk, BCG-unresponsive disease face limited treatment options, making innovative therapies like ADSTILADRIN especially important.
The newly approved thawing method directly addresses a practical challenge faced in clinical environments. Traditionally, frozen therapies can require extended thawing times, which may delay treatment schedules and increase logistical complexity. The ability to safely thaw ADSTILADRIN in just 25 minutes represents a meaningful improvement, enabling healthcare teams to prepare and administer treatment more quickly and efficiently.
Clinical and Operational Benefits
According to medical experts, this updated process has the potential to significantly improve clinical workflows. Faster preparation times allow healthcare providers to better manage patient scheduling and reduce wait times, ultimately enhancing the delivery of care.
Dr. Vikram M. Narayan, Associate Professor at Emory University Department of Urology and Chief of Urology at Grady Memorial Hospital, emphasized the importance of this advancement. He noted that reducing thawing time simplifies handling procedures and may allow providers to treat more patients within the same timeframe. This efficiency can be particularly valuable in busy clinical settings where time and resources are limited.
In addition to saving time, the updated thawing protocol provides greater flexibility for healthcare teams. The ability to prepare the therapy more quickly can help accommodate unexpected schedule changes and improve overall clinic operations.
Scientific Validation of Stability
The FDA’s approval of the label update is supported by robust scientific data. A dedicated thawing and handling study demonstrated that ADSTILADRIN maintains its stability when thawed using the accelerated water-bath method at 25°C for approximately 25 minutes.
Importantly, the updated process does not alter the product’s storage conditions after thawing begins. Once thawed, ADSTILADRIN can still be stored for up to 24 hours at room temperature (20°C to 25°C) or refrigerated (2°C to 8°C) for up to seven days, including the thawing period. This consistency ensures that healthcare providers can adopt the new method without needing to adjust existing storage protocols.
The confirmation of product stability under these conditions reinforces confidence in the therapy’s safety and effectiveness, even with the faster preparation time.
Commitment to Innovation and Patient-Centered Care
Ferring Pharmaceuticals highlighted that this label update reflects its ongoing commitment to improving both patient outcomes and provider experiences. By continuously refining the delivery and handling of its therapies, the company aims to address real-world challenges faced in clinical practice.
Denise D’Andrea, MD, Senior Director of Medical Affairs in Uro-Oncology at Ferring, emphasized that innovation extends beyond the development of new treatments. She noted that optimizing how therapies are administered can have a meaningful impact on patient care.
ADSTILADRIN already offers a convenient dosing schedule of once every three months, reducing the frequency of clinic visits and easing the burden on patients. The addition of a faster thawing method further enhances its practicality, making it easier for healthcare providers to integrate the therapy into routine clinical workflows.
This combination of clinical effectiveness and operational convenience underscores the therapy’s value in modern oncology care.
Mechanism and Administration
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy administered directly into the bladder via intravesical instillation. It works by delivering a gene that enables cells to produce interferon alfa-2b, a protein with anti-tumor activity, thereby helping the body fight cancer at the site of disease.
The therapy is supplied as a sterile frozen suspension and must be brought to room temperature before administration. The newly approved thawing method simplifies this step, ensuring that the therapy can be prepared quickly without compromising its integrity.
It is important to note that ADSTILADRIN is strictly intended for intravesical use and should not be administered intravenously, orally, or topically.
Important Safety Information
As with any medical therapy, ADSTILADRIN carries specific safety considerations that healthcare providers must carefully evaluate.
Contraindications:
The therapy is contraindicated in patients with a history of hypersensitivity reactions to interferon alfa or any component of the product.
Warnings and Precautions:
One key risk associated with treatment is the potential consequence of delaying cystectomy (surgical removal of the bladder). In patients with BCG-unresponsive CIS, postponing this procedure could lead to progression to muscle-invasive or metastatic bladder cancer, which can be life-threatening. If patients do not achieve a complete response within three months or experience recurrence, cystectomy should be considered.
Another important consideration is the risk of disseminated adenovirus infection. Because ADSTILADRIN uses an adenoviral vector, individuals who are immunocompromised or immunodeficient may be at increased risk of infection. Exposure to such individuals should be avoided.
Use in Specific Populations:
Patients of reproductive potential are advised to use effective contraception during treatment. Females should continue contraception for six months after the last dose, while males with female partners of reproductive potential should continue for three months after treatment.
Adverse Reactions:
Common adverse reactions observed in clinical use include increased glucose levels, instillation site discharge, elevated triglycerides, fatigue, bladder spasms, urinary urgency, increased creatinine, hematuria (blood in urine), decreased phosphate levels, chills, fever, and dysuria (painful urination). Monitoring and appropriate management of these effects are essential during treatment.
Enhancing the Future of Oncology Care
The FDA’s approval of this label update represents more than a procedural improvement—it highlights the growing importance of optimizing treatment delivery in addition to developing innovative therapies. By addressing practical challenges such as preparation time, healthcare companies can significantly improve the real-world usability of their products.
For patients with high-risk NMIBC, timely and efficient treatment is critical. The ability to prepare ADSTILADRIN more quickly may help ensure that patients receive therapy without unnecessary delays, potentially improving outcomes and overall satisfaction with care.
As healthcare systems continue to evolve, innovations like this accelerated thawing method demonstrate how incremental improvements can make a meaningful difference. By focusing on both clinical efficacy and operational efficiency, Ferring Pharmaceuticals is helping to advance the standard of care for bladder cancer patients.
About ADSTILADRIN
ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1). It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter directly into the bladder once every three months. The vector enters the cells of the bladder wall, releasing the active gene and causing the bladder’s cell walls to secrete high and transient local expression of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This approach essentially turns the bladder wall cells into interferon microfactories, enhancing the body’s own natural defenses against the cancer.
ADSTILADRIN has been studied in a clinical trial program that includes 157 patients with high-risk, BCG-unresponsive NMIBC, who had been treated with adequate BCG previously and did not see benefit from additional BCG treatment (full inclusion criteria published on clinicaltrials.gov: NCT02773849 and final five-year follow-up analysis published in The Journal of Urology).
